2. Bakgrunn

Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019). From NASH to HCC: current concepts and future challenges. Nature Reviews: Gastroenterology & Hepatology, 16(7), 411-428.

Baran, B. (2015). Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World Journal of Hepatology, 7(13), 1742-54.

Brynestad, F. (2022). Personlig meddelselse sendt på e-post til Oddvar Sandvik Oslo: Kreftregisteret.

Eskesen, A. N., Bjoro, K., Aandahl, E. M., Line, P. D., & Melum, E. (2014). Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway--a population-based cohort study. Cancer Epidemiology, 38(6), 741-7.

European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69(1), 182-236.

Haukeland, J. W., Smastuen, M. C., Palsdatter, P. P., Ismail, M., Konopski, Z., Jorgensen, K. K., Lannerstedt, H., & Midgard, H. (2020). Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway. PloS One, 15(3), e0230263.

IARC (2020). Liver fact sheet: Source: Globocan 2020 Lyon: International Agency for Research on Cancer. Hentet fra https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf

Ioannou, G. N., Green, P. K., & Berry, K. (2017). HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. Journal of Hepatology,

Jepsen, P., Ott, P., Andersen, P. K., Sorensen, H. T., & Vilstrup, H. (2012). Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Annals of Internal Medicine, 156(12), 841-7, W295.

Johannessen, A., Rojahn, A., Reikvam, D. H., Skjefte, H., Tveter, I., Haukeland, J. W., ... Karlsen, L. N. (2022). Faglig veileder for utredning og behandling av hepatitt B Oslo: Norsk forening for infeksjonsmedisin, Norsk forening for medisinsk mikrobiologi, Norsk gastroenterologisk forening, Norsk barnelegeforening og Norsk forening for allmennmedisin i Den norske legeforening. Hentet fra https://www.legeforeningen.no/contentassets/8202dc0b6aaa4f3b8cb85c46a8ed7709/veileder-hepatitt-b-2022.pdf

Kennedy, O. J., Roderick, P., Buchanan, R., Fallowfield, J. A., Hayes, P. C., & Parkes, J. (2017). Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open, 7(5), e013739.

Kew, M. C. (2003). Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver international, 23(6), 405-9.

Larsen, I. K. (2022). Cancer in Norway 2021: Cancer incidence, mortality, survival and prevalence in Norway. Cancer Reistry of Norway.

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., ... Finn, R. S. (2021). Hepatocellular carcinoma. Nature reviews. Disease primers, 7(1), 6.

Lockart, I., Yeo, M. G. H., Hajarizadeh, B., Dore, G. J., & Danta, M. (2022). HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology,

Lok, A. S., Seeff, L. B., Morgan, T. R., di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., ... Group, H. C. T. (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology, 136(1), 138-48.

Matsushita, H., & Takaki, A. (2019). Alcohol and hepatocellular carcinoma. BMJ open gastroenterology, 6(1), e000260.

Midgard, H., Frigstad, S. O., & Haukeland, J. W. (2021). NAFLD: Leverens manifestasjon av det metabolske syndrom. NGF-nytt, 28(3), 8-14.

Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., ... Hickman, M. (2018). Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction, 113(3), 545-563.

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7-33.

Simon, T. G., Duberg, A. S., Aleman, S., Chung, R. T., Chan, A. T., & Ludvigsson, J. F. (2020). Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. New England Journal of Medicine, 382(11), 1018-1028.

Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013). Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology, 144(2), 323-332.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249.

Trinchet, J. C., Bourcier, V., Chaffaut, C., Ait Ahmed, M., Allam, S., Marcellin, P., Guyader, D., Pol, S., ... Group, A. C. C. (2015). Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology, 62(3), 737-50.

Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015). Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 149(2), 367-78 e5; quiz e14-5.

Villanueva, A. (2019). Hepatocellular Carcinoma. New England Journal of Medicine, 380(15), 1450-1462.

Wang, J., Chenivesse, X., Henglein, B., & Brechot, C. (1990). Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature, 343(6258), 555-7.

WHO (24. juni 2022). Hepatitis C: key facts. [nettdokument]. Geneva: World Health Organization. Hentet 16. oktober 2022 fra https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews: Gastroenterology & Hepatology, 15(1), 11-20.